225-OR: Sequential Islet Transplants for Type 1 Diabetes Do Not Cumulatively Increase Hepatic Portal Venous Pressure
Bibliographic record
Abstract
The future of islet transplantation (ITx) is rapidly moving towards stem-cell based therapies, which have led to short term insulin independence when delivered into the hepatic portal vein. It is likely that multiple infusions will be needed to maintain insulin independence long term. We examined the effects of sequential ITx on portal pressures and if features of the transplanted preparation influence acute changes in portal pressure. We include data from adults undergoing intraportal ITx at the University of Alberta Hospital between May 1999 to April 2023. We assessed, by pairwise comparison, acute changes in portal pressure at each ITx infusion and used linear mixed-effects models to: 1) compare sequential pre-infusion portal pressure with reference to pre-first ITx infusion and 2) assess the relationship between change in portal pressure and packed cell volume (PCV), purity and islet equivalents per kilogram (IEQ/kg). We include 299 adults (44% M) who received up to 5 (median of 2 [IQR 2-3]) ITx infusions and a median total 15,220 IEQ/kg [IQR 11,324, 19,700]. The median purity across all ITx infusions was 55% [IQR 45, 70] with a median PCV of 3ml [IQR 2.5, 4]. The total time to final ITx was a median 11m [IQR 2-50]. Portal pressure acutely increased after each ITX infusion (p<0.001) by a median 2.0 mmHg [IQR 1.0-4.0]. This acute rise was not sustained however, with sequential pre-infusion portal pressure returning to similar levels (p>0.1) as that pre-first ITx infusion (median 11.0 mmHg [IQR 8.0-14.0]). PCV had the strongest correlation with post-infusion change in portal pressure, with a 1 mmHg increase in portal pressure per 1 ml of PCV (Slope: 1.09 [95% CI0.93,1.26]; p<0.001). Sequential ITx do not increase portal pressure or amplify changes during supplementary infusions. Higher PCV may exacerbate acute rises in portal pressures. Insights from deceased-donor intraportal ITx can inform safe implementation of future stem-cell based therapies in people living with diabetes. Disclosure A.L.J. Carr: None. R. Shah: None. B.A. Marfil-Garza: None. A. Lam: None. B.L. Anderson: None. D. O'Gorman: None. T. Kin: None. D. Bigam: None. A. Shapiro: Consultant; Vertex Pharmaceuticals Incorporated, Betalin Therapeutics, Hemostemix Inc, ViaCyte, Inc., Aspect Biosystems. P.A. Senior: Consultant; Abbott, Bayer Inc., Dexcom, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Insulet Corporation, Novo Nordisk Canada Inc., Sanofi, Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Abbott, Dexcom, Inc., Insulet Corporation, Novo Nordisk Canada Inc. Research Support; Novo Nordisk Canada Inc.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.008 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".